Chesley Taft & Associates Boosts Stake in Eli Lilly

Investment firm increases holdings in pharmaceutical giant by 7.3% in Q4 2025

Mar. 31, 2026 at 8:04am

Got story updates? Submit your updates here. ›

Chesley Taft & Associates LLC, a Chicago-based investment management firm, increased its stake in Eli Lilly and Company by 7.3% during the fourth quarter of 2025, according to a recent SEC filing. The firm now owns 22,441 shares of the pharmaceutical company's stock, valued at approximately $24.1 million.

Why it matters

Eli Lilly is one of the world's largest and most influential pharmaceutical companies, with a diverse portfolio of blockbuster drugs. Institutional investors closely monitor changes in ownership of Lilly's stock, as it can signal broader market sentiment and future growth potential for the company.

The details

Chesley Taft & Associates added 1,518 shares of Eli Lilly to its portfolio during the fourth quarter, bringing its total holdings to 22,441 shares. This represents approximately 1% of the firm's total assets under management. The investment decision was likely driven by Eli Lilly's strong financial performance and promising drug development pipeline, which have made the stock an attractive long-term holding for many institutional investors.

  • Chesley Taft & Associates increased its Eli Lilly stake during the fourth quarter of 2025.
  • The firm's latest 13F filing with the SEC was released on March 31, 2026.

The players

Chesley Taft & Associates LLC

A Chicago-based investment management firm that oversees approximately $2.4 billion in client assets.

Eli Lilly and Company

A global pharmaceutical company headquartered in Indianapolis, Indiana, known for its innovative drug development and commercialization.

Got photos? Submit your photos here. ›

The takeaway

Chesley Taft's increased stake in Eli Lilly reflects the firm's confidence in the pharmaceutical company's long-term growth prospects, driven by its diverse product pipeline and market leadership. This move aligns with the broader trend of institutional investors seeking exposure to large, established healthcare companies that can provide stability and consistent returns.